In May 2026, Medtronic successively announced a series of major executive appointments, indicating that the company has implemented a new management structure across its supply chain, neuroscience, and cardiovascular surgery divisions.
 
Recent reports indicate that Brett Wall, Executive Vice President and President of Medtronic’s Neuroscience Portfolio, will step down, with the appointment of his successor taking effect on June 1. It is understood that prior to joining Medtronic, Brett Wall held positions at ev3, Micro Therapeutics, Boston Scientific, and other companies. His successor will be Dr. Kweli Thompson, who currently serves as Senior Vice President and President of Medtronic’s Cardiac Rhythm Management business.

On May 13, Medtronic announced the appointment of Rogerio Branco as Senior Vice President and Chief Operating and Supply Chain Officer, effective immediately. Public information indicates that Branco previously served as Executive Vice President and Chief Operating and Supply Chain Officer at Eaton, a power management company headquartered in Dublin, Ireland, where he was responsible for integrated materials management and inventory, procurement, logistics, supplier development, and quality. Upon joining Medtronic, he will lead the strategy and execution of the company’s end-to-end operations and supply chain to drive reliability, efficiency, and growth, while serving patients and customers worldwide.

On May 6, Medtronic completed a major organizational restructuring, merging the Cardiac Surgery and Aortic divisions into the Cardiovascular Surgery division. Following the merger, the newly established business unit will be led by Karim Bandali. It is reported that Simona Zannetti, former head of the Aortic business, departed in early 2026.

In addition to frequent personnel adjustments, Medtronic has also executed multiple mergers, acquisitions, and divestitures across its business portfolio this year. On May 20, Medtronic announced that it has agreed to acquire all outstanding equity of chronic pain management company SPR Therapeutics in cash for approximately $650 million (approximately RMB 4.4 billion). SPR Therapeutics' core product is the Sprint peripheral nerve stimulation (PNS) system, which received FDA approval for commercialization in 2018. As of the end of 2025, the cumulative implant volume for this device has surpassed 50,000 cases.

On April 20, Medtronic announced the completion of its acquisition of CathWorks, a developer of artificial intelligence cardiac technologies, in a transaction valued at up to $585 million. CathWorks focuses on revolutionizing the diagnostic and therapeutic paradigm for coronary artery disease (CAD). As early as 2018, Medtronic had already acquired a minority stake in the company.

On March 10, Medtronic announced the acquisition of neurovascular device company Scientia Vascular for $550 million (approximately RMB 3.9 billion), with the transaction expected to close in the first half of fiscal year 2027. Scientia has been deeply engaged in the neurointerventional sector for years, and its core products include precision medical consumables such as microguidewires and microcatheters, which are essential for stroke procedures.

In the same month, Medtronic's diabetes business was officially spun off into an independent company, MiniMed, and listed on the Nasdaq. The company issued 28 million shares at an offering price of $20 per share, raising approximately $560 million.

Overall, in 2026, Medtronic is implementing a three-pronged strategy of organizational streamlining, targeted M&A, and executive leadership renewal to build new competitive advantages in high-growth segments such as cardiovascular and neuroscience. Whether the company can deliver the accelerated growth anticipated by the market is expected to depend primarily on the integration effectiveness of its neurovascular portfolio and the capital allocation efficiency following the divestiture of its diabetes business.

Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.